Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Altimmune, Inc.

Get SEC filing alerts via email and in your feed for Altimmune, Inc.

ALT

Altimmune, Inc.

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics targeting obesity, metabolic, and liver diseases. Its lead product, pemvidutide, is a dual GLP-1/glucagon receptor agonist designed to promote weight loss, reduce liver fat, and improve metabolic health. Altimmune focuses on innovative treatments addressing comorbidities of obesity and metabolic-associated steatohepatitis (MASH), leveraging proprietary technology and clinical development to serve patients with unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Altimmune, Inc.

1
1
Altimmune, Inc. Altimmune Reports $22.6 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Altimmune, Inc. Altimmune Reports $88.1 Million Net Loss for Fiscal Year 2025, Plans Phase 3 Trial for Pemvidutide

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Altimmune, Inc. Altimmune Reports Decreased Net Loss and Stable Revenue in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Altimmune, Inc. Altimmune Reports Q2 2025 Financial Results with Reduced Net Loss and Increased Cash Reserves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Altimmune, Inc. Altimmune Reports Q1 2025 Financial Results with Reduced Net Loss and Increased Assets

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Altimmune, Inc. Altimmune Reports $95.1 Million Net Loss and Minimal Revenue for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Altimmune, Inc. Altimmune Reports Significant Financial Decline, Increased R&D Expenses, and Diminished Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments